Impedimed and Alchemia

About the author:

Author name:

By Scott Power

Job title:

Senior Analyst

Date posted:

09 October 2014, 10:27 AM

Sectors Covered:

Healthcare, Life Sciences

Two stocks to have in a speculative portfolio ahead of major milestones:

Alchemia (ACL)

• Alchemia's top line Phase 3 metastatic colorectal cancer results due before end of October

Impedimed (IPD)

• Impedimed's reimbursement rates will be determined by the Centres for Medicare and Medicaid Services in November

I am very positive on both stories - if you don't have them in the portfolio now is the time to Buy.

More information

Morgans clients should login to view more detailed analysis on Alchemia and Impedimed. Alternatively, for more information contact your adviser or nearest Morgans office.

Disclaimer(s): Analyst owns shares. 

The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents ("Morgans") do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.